Poseida Therapeutics, Inc.
NEWS
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
Clinical Catch-Up for February 21
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
Celares and Mission Bio are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with.
Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.
Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day.
There were a fair number of clinical trial announcements last week. Here’s a look.
The 24th Annual meeting of the American Society of Gene & Cell Therapy presents cutting-edge work in the booming area of gene and cell therapy. Here’s a look at a few of the highlights.
JOBS
IN THE PRESS